文献速递眼底病与葡萄膜炎

IVAN试验:抗VEGF治疗nAMD中病灶内黄斑萎缩的发生与进展

Intralesional Macular Atrophy in Anti-Vascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration in the IVAN Trial.
PubMed 文献 · Ophthalmology · 2018-10-06

该研究基于IVAN随机对照试验的影像数据,系统评估了抗VEGF治疗新生血管性年龄相关性黄斑变性(nAMD)2年内病灶内黄斑萎缩(MA)的发生率及其与形态和功能指标的关系。结果显示,研究眼病灶内MA的2年累积发生率为24.4%,病灶外MA仅1.54%;基线≥50%经典型CNV、末次访视时视网膜下液或色素上皮脱离与病灶内MA发生风险降低相关,未发现MA与药物或治疗频率及视功能指标存在显著关联。

要点

  • 抗VEGF治疗2年内,24.4%的研究眼发生病灶内MA,病灶外MA罕见(1.54%)。
  • 基线≥50%经典型CNV及末次访视时SRF或PED与病灶内MA风险降低相关。
  • 未发现病灶内MA发生与药物种类、治疗频率或视功能指标存在显著关联。

核心结论

  • 接受抗VEGF治疗的nAMD眼在2年内常在病灶内发生黄斑萎缩,但未发现其与药物或治疗频率及视功能指标相关。

研究设计与样本

  • 基于IVAN随机对照试验的读片中心分析,纳入研究眼既往未治疗的nAMD参与者,研究眼数据可分析594/610例。
  • 基线及2年随访期间系统判读彩色眼底、荧光素血管造影(FA)和OCT图像以评估MA。

主要发现

  • 研究眼基线病灶内MA占9.6%,末次访视时新发病灶内MA占24.4%,病灶外MA仅1.54%。
  • 对侧眼基线存在nAMD病灶者248例,其中16.9%基线有病灶内MA,12.9%新发病灶内MA。
  • 研究眼基线≥50%经典型CNV(OR 0.39;95%CI 0.19-0.80;P=0.010)、末次访视时视网膜下液(OR 0.41;95%CI 0.25-0.76;P=0.004)或色素上皮脱离(OR 0.40;95%CI 0.21-0.74;P=0.004)与新发病灶内MA风险降低相关。
  • 对侧眼基线存在病灶内MA与研究眼新发或进展病灶内MA风险升高相关(OR 2.43;95%CI 1.09-5.44;P=0.030)。
  • 未观察到病灶内MA发生与任何其他形态或视功能指标存在显著关联。

关键数值与推荐

  • 病灶内MA定义为FA和/或彩色眼底(辅以OCT)所见脉络膜血管最大线性尺寸≥175 μm且位于新生血管病灶最大范围之内。

临床怎么用

  • 抗VEGF治疗中病灶内MA常见,但本研究未发现其与药物或治疗频率相关,可为临床医生提供一定 reassurance。
  • 基线经典型CNV比例高、末次访视时存在SRF或PED的患眼病灶内MA风险较低,对侧眼有病灶内MA者风险较高。

局限性

  • MA的长期影响尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report on the development and progression of macular atrophy (MA) and its relationship with morphologic and functional measures in study and fellow eyes in the Inhibition of vascular endothelial growth factor (VEGF) in Age-related Choroidal Neovascularisation trial. DESIGN: Reading center analysis of data from a randomized controlled trial. PARTICIPANTS: Participants with previously untreated neovascular age-related macular degeneration (nAMD) in the study eye. METHODS: Color, fluorescein angiography (FA) and OCT images acquired at baseline and during the 2-year follow-up were graded systematically for presence of MA. Regression models were constructed to explore relationships between MA and lesion morphology and vision measures (best-corrected distance and near acuity, reading speed and index, contrast sensitivity). MAIN OUTCOME MEASURES: Primary outcome was development of intralesional MA (≥175 μm greatest linear dimension of choroidal vessels seen on FA and/or color, aided by OCT) lying within the maximum footprint of the neovascular lesion. RESULTS: Study eye data were available for 594 of 610 participants; 57 (9.6%) showed intralesional MA at baseline. Incident intralesional MA occurred in 24.4% by the final visit and extralesional MA in only 1.54%. In fellow eyes, an established nAMD lesion was present at baseline in 248 of whom 42 (16.9%) showed intralesional MA at baseline and 32 (12.9%) developed incident intralesional MA. The odds of incident intralesional MA by final visit were lower in study eyes that had ≥50% classic CNV at baseline (odds ratio [OR], 0.39; 95% confidence interval [CI], 0.19-0.80; P = 0.010), subretinal fluid at final visit (OR, 0.41; 95% CI, 0.25-0.76; P = 0.004), or pigment epithelial detachment at final visit (OR, 0.40; 95% CI, 0.21-0.74; P = 0.004). Secondary analyses of incident or progressed intralesional MA in study eyes supported these findings, with odds increasing if the fellow eye had baseline intralesional MA (OR, 2.43; 95% CI, 1.09-5.44; P = 0.030). No significant associations were observed between development of intralesional MA and any other morphologic or visual function measure. CONCLUSIONS: Macular atrophy frequently develops within an nAMD lesion in eyes receiving anti-VEGF therapy over 2 years. No associations between incident MA and drug or treatment frequency or visual function were detected, providing some reassurance to clinicians; however, the longer-term effects remain unknown.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Bailey C, Scott LJ, Rogers CA, et al. Intralesional Macular Atrophy in Anti-Vascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration in the IVAN Trial. Ophthalmology. 2018. PMID: 30301555. doi:10.1016/j.ophtha.2018.07.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。